Zoptarelin Doxorubicin

N/A

Report date: 2024/06/27 20:00:09
NME

Base Information

Drug NameZoptarelin Doxorubicin
Drug Alias Namezoptarelina doxorubicina多柔比星佐他瑞林佐他柔比星zoptarelinum doxorubicinumDoxorubicin-GnRH agonist conjugate +[10] 
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionGonadotropin-releasing hormone receptor agonistsTopoisomerase II inhibitors
TargetsTopoisomerase IIGonadotropin-releasing hormone receptor
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsProstatic NeoplasmsEndometrial Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[22] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTulane University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Southern CaliforniaCOSCIENS Biopharma IncSinopharm A-Think Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate NeoplasmsProstatic NeoplasmsEndometrial Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia